Meeting
2016 Genitourinary Cancers Symposium
The impact of contrast enhancement reduction on tumor response in patients with advanced renal cell carcinoma that treated with presurgical targeting therapy.
Authors
Shingo Hatakeyama
Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
Shingo Hatakeyama , Takahiro Yoneyama , Yasuhiro Hashimoto , Takuya Koie , Chikara Ohyama
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 510)
DOI
10.1200/jco.2016.34.2_suppl.510
Abstract #
510
Poster Bd #
D15
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
Sequential treatment of advanced or metastatic renal cell carcinoma (mRCC): What is effective? Data from the German RCC registry.
First Author: Lothar Mueller
Poster
2013 ASCO Annual Meeting
Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET).
First Author: Timothy J. Hobday
Poster
2023 ASCO Genitourinary Cancers Symposium
The survival outcomes of metastatic non-clear cell renal cell carcinoma in the immunotherapy era: Princess Margaret Cancer Centre (PMCC) experience.
First Author: Esmail Mutahar Al-Ezzi
Poster
2022 ASCO Annual Meeting
ALTER-UC-001: Phase II trial of anlotinib plus everolimus as first-line treatment for advanced non–clear cell renal cell carcinoma.
First Author: Hailiang Zhang